文献速递心境障碍会诊联络精神医学

胰岛素抵抗与抑郁症更差治疗结局:英国生物银行初级保健数据

Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data.
PubMed 文献 · Br J Psychiatry · 2025-06-23

基于英国生物银行初级保健记录,研究纳入30 919例重性抑郁障碍(MDD)患者,其中51.95%伴终生胰岛素抵抗相关疾病。伴胰岛素抵抗者抗抑郁药处方与类别更多、疗程更长,且胰岛素抵抗相关疾病与抗抑郁药无应答/抵抗及更长疗程相关,未发现相关多基因评分与治疗结局的显著关联。

要点

  • 伴胰岛素抵抗相关疾病的MDD患者抗抑郁药使用更多、疗程更长。
  • 胰岛素抵抗相关疾病与抗抑郁药无应答/抵抗相关,MDD先于代谢病时更明显。
  • 胰岛素抵抗相关多基因评分与抗抑郁治疗结局无显著关联。

核心结论

  • MDD患者中胰岛素抵抗相关疾病与更差的抗抑郁治疗结局相关,支持精神与代谢整合治疗。

研究设计与样本

  • 基于英国生物银行初级保健记录,识别30 919例MDD病例及胰岛素抵抗相关疾病与治疗结局指标。
  • 采用单因素分析比较伴(IR+)与不伴(IR-)终生胰岛素抵抗相关疾病的MDD病例,并用多元回归校正混杂因素。
  • 胰岛素抵抗相关多基因评分(PGS)采用PRS-CS计算。

主要发现

  • 30 919例MDD病例中51.95%为IR+。
  • IR+者抗抑郁药处方与类别更多、疗程更长(P < 0.001)。
  • IR+者抑郁特征包括注意力问题、孤独感和无用感,并随MDD与胰岛素抵抗相关疾病诊断先后而变化。
  • 校正混杂后,胰岛素抵抗相关疾病与抗抑郁药无应答/抵抗及更长疗程相关,尤其当MDD先于胰岛素抵抗相关疾病时。
  • 未发现胰岛素抵抗相关PGS与抗抑郁治疗结局的显著关联。

关键数值与推荐

  • IR+定义为伴终生胰岛素抵抗相关疾病,包括心血管疾病、高血压、非酒精性脂肪性肝病、肥胖/超重、糖尿病前期和2型糖尿病。
  • IR+者较IR-者抗抑郁药处方与类别更多、疗程更长,P < 0.001。

临床怎么用

  • 对MDD患者应同时评估代谢健康,优先采取精神与代谢整合治疗。
  • 对伴胰岛素抵抗相关疾病者,尤其MDD先于代谢病者,需关注抗抑郁药无应答/抵抗与更长疗程。
  • 公共卫生策略应重视MDD患者胰岛素抵抗的早期干预与预防。

局限性

  • 原文摘要未报告具体局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Major depressive disorder (MDD) and insulin resistance-related conditions are major contributors to global disability. Their co-occurrence complicates clinical outcomes, increasing mortality and symptom severity. AIMS: In this study, we investigated the association of insulin resistance-related conditions and related polygenic scores (PGSs) with MDD clinical profile and treatment outcomes, using primary care records from UK Biobank. METHOD: We identified MDD cases and insulin resistance-related conditions, as well as measures of depression treatment outcomes (e.g. resistance) from the records. Clinical-demographic variables were derived from self-reports, and insulin resistance-related PGSs were calculated using PRS-CS. Univariable analyses were conducted to compare sociodemographic and clinical variables of MDD cases with (IR+) and without (IR-) lifetime insulin resistance-related conditions. Multiple regressions were performed to identify factors, including insulin resistance-related PGSs, potentially associated with treatment outcomes, adjusting for confounders. RESULTS: Among 30 919 MDD cases, 51.95% were IR+. These had more antidepressant prescriptions and classes utilisation and longer treatment duration than patients without insulin resistance-related conditions (P < 0.001). IR+ participants showed distinctive depressive profiles, characterised by concentration issues, loneliness and inadequacy feelings, which varied according to the timing of MDD diagnosis relative to insulin resistance-related conditions. After adjusting for confounders, insulin resistance-related conditions (i.e. cardiovascular diseases, hypertension, non-alcoholic fatty liver disease, obesity/overweight, prediabetes and type 2 diabetes mellitus) were associated with antidepressant non-response/resistance and longer treatment duration, particularly when MDD preceded insulin resistance-related conditions. No significant PGS associations were found with antidepressant treatment outcomes. CONCLUSIONS: Our findings support an integrated treatment approach, prioritising both psychiatric and metabolic health, and public health strategies aimed at early intervention and prevention of insulin resistance in MDD.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fanelli G, Bralten J, Franke B, et al. Insulin resistance and poorer treatment outcomes in depression: evidence from UK Biobank primary care data. Br J Psychiatry. 2025. PMID: 40548411. doi:10.1192/bjp.2025.82

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。